Drug developer QLT to appeal injunction against Eligard sales in U.S.

VANCOUVER (CP) - Drug developer QLT Inc. (TSX:QLT) plans to appeal a U.S. court decision that has placed an injunction on production and sales of its Eligard treatment for prostate cancer....More